Comment on 'High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. ' There is a growing interest worldwide in understanding potential crossreaction of PDE5 inhibitors with other proteins and we agree with the authors that PDE11 is one of the obvious candidates, since it is closely related to the PDE5. Weeks et al should be congratulated because, comparing the potencies of tadalafil, vardenafil and sildenafil for PDE11A4 and the fold selectivity of these inhibitors for PDE5A1 over PDE11A4, they provide several important information for safety issues. We focused our attention on the conclusions of the authors. Whereas we perfectly agree that 'the fold selectivity for PDE5 over PDE11A4 for sildenafil (1000-fold selectivity) and vardenafil (9000-fold selectivity) reveals that these drugs are very unlikely to crossreact with PDE11A4 in patients treated with these medications', 1 on the contrary, we would suggest caution concerning the newest PDE-5 inhibitor tadalafil. In fact, the 40-fold selectivity ratio of tadalafil for PDE5 over PDE11A4, found in this study, significantly lower than those reported with the other two drugs, is nearly the same of that reported for sildenafil over PDE1 (41-fold). In this case, it has been suggested that the 41-fold selectivity of sildenafil for PDE5 over PDE1 may induce vasodilatation, flushing and tachycardia. Moreover, Weeks et al studied and gave information only on PDE11A4, which is one among four of the identified human PDE11A splice variants. Probably 'PDE11A4, containing the most extensive regulatory domain structure, is highly regulated and plays an important physiological role', 1 but, since tadalafil is a nonspecific PDE11A4 inhibitor, we believe that for safety purpose we should consider the possible crossreaction with all the four human PDE11 variants. This global evaluation may provide the highest therapeutic benefits/undesirable side effects ratio. For these reasons, we do not believe that all safety issues on tadalafil crossreaction with PDE11 are satisfied. Within human PDE11A family, the alternatively spliced isoforms display unique tissue expression and specificity.
There is a growing interest worldwide in understanding potential crossreaction of PDE5 inhibitors with other proteins and we agree with the authors that PDE11 is one of the obvious candidates, since it is closely related to the PDE5. Weeks et al should be congratulated because, comparing the potencies of tadalafil, vardenafil and sildenafil for PDE11A4 and the fold selectivity of these inhibitors for PDE5A1 over PDE11A4, they provide several important information for safety issues.
We focused our attention on the conclusions of the authors. Whereas we perfectly agree that 'the fold selectivity for PDE5 over PDE11A4 for sildenafil (1000-fold selectivity) and vardenafil (9000-fold selectivity) reveals that these drugs are very unlikely to crossreact with PDE11A4 in patients treated with these medications', 1 on the contrary, we would suggest caution concerning the newest PDE-5 inhibitor tadalafil. In fact, the 40-fold selectivity ratio of tadalafil for PDE5 over PDE11A4, found in this study, significantly lower than those reported with the other two drugs, is nearly the same of that reported for sildenafil over PDE1 (41-fold). In this case, it has been suggested that the 41-fold selectivity of sildenafil for PDE5 over PDE1 may induce vasodilatation, flushing and tachycardia. 2 Moreover, Weeks et al studied and gave information only on PDE11A4, which is one among four of the identified human PDE11A splice variants. Probably 'PDE11A4, containing the most extensive regulatory domain structure, is highly regulated and plays an important physiological role', 1 but, since tadalafil is a nonspecific PDE11A4 inhibitor, we believe that for safety purpose we should consider the possible crossreaction with all the four human PDE11 variants. This global evaluation may provide the highest therapeutic benefits/undesirable side effects ratio. For these reasons, we do not believe that all safety issues on tadalafil crossreaction with PDE11 are satisfied. Within human PDE11A family, the alternatively spliced isoforms display unique tissue expression and specificity.
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PDE11A4 is expressed in the prostate gland and unlikely it could be related to the tadalafil-related side effects, back-pain and alteration of sperm quality.
PDE11A1 is predominantly present in skeletal muscle and, as the authors remember, there are studies reporting a low selectivity (five-fold) of tadalafil for PDE5 over PDE11A1. 2 This enzyme and its inhibition could account for the back pain, reported by some men taking tadalafil. In our opinion, the 'back-pain', 'specific pain felt in the low or upper back', should be considered a tadalafilspecific-side effect, more than 'myalgia', 'pain in a nonspecific muscle', which has been reported even with sildenafil or vardenafil.
We have not many information on PDE11A2, but its transcripts were detected in various tissues including brain, lung, skeletal muscle, spleen, testis and prostate. PDE11A3 is present predominantly in the testes and its inhibition could produce alteration in the quality of sperm of some patients taking tadalafil. This hypothesis is consistent with the results of our preliminary report, which investigate for the first time the effect of tadalafil administration on men with fertility problems. Tadalafil, compared to the baseline, caused a statistically significant decrease of spermatozoa with rapid progressive motility (12.3%72.2 vs 9%71.9 (Po0.05)). 4 Moreover, surprisingly our results are comparable with those reported in mice knock out for the PDE11. 'Ejaculated sperm from PDE11KO mice had a reduced rate of forward progression compared with WT mice (range ¼ 1 (low) to 4 (high); 2.270.2 vs 2.970.1, Po0.05),'.
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In light of these findings, we believe that PDE11 inhibition impacts on sperm quality. Reasonable caution should be suggested in patients taking the prescribed dosages of tadalafil, the only PDE5 inhibitor to date which could crossreact with human PDE11A splicing variants.
